MENU
MBOT
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Microbot Medical (MBOT) Ownership - Who owns Microbot Medical?

Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space... Show more

Industry: #Biotechnology
A.I.Advisor
Nov 12, 2026

What Is Microbot Medical (MBOT)? Company Overview, Business Model and Market Position

Key Takeaways

  • MBOT is the Nasdaq ticker for Microbot Medical Inc., a commercial-stage medical device company focused on endovascular robotics.
  • The company's flagship product, the LIBERTY Endovascular Robotic System, is the first FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures.
  • Microbot Medical was founded in 2010 and is headquartered in Hingham, Massachusetts, with a research and development heritage in Israel.
  • The company received FDA 510(k) clearance for LIBERTY in September 2025 and began full U.S. commercialization in 2026.
  • Microbot Medical targets a large U.S. market of roughly 2.5 million peripheral endovascular procedures annually, positioning itself in the emerging field of medical robotics.

Introduction

Microbot Medical Inc. is a commercial-stage medical device company developing robotic technology designed to transform minimally invasive endovascular procedures. Traded on the Nasdaq under the ticker MBOT, the company has attracted investor attention as an early entrant in the fast-growing surgical and interventional robotics space. Its core innovation, the LIBERTY Endovascular Robotic System, aims to improve precision during catheter-based procedures while reducing physician radiation exposure and physical strain — a company overview that places Microbot at the intersection of medical devices, robotics, and outpatient care.

Main Profile

Microbot Medical was founded in 2010 and is headquartered in Hingham, Massachusetts, while maintaining a significant research and development presence rooted in Israel. The company is a commercial-stage enterprise, meaning it has only recently transitioned from product development to generating sales revenue.

Core Products and Technology

The company's flagship product is the LIBERTY Endovascular Robotic System. LIBERTY is a single-use, remotely operated robotic platform designed to maneuver guidewires, microcatheters, and other over-the-wire devices within the body's vasculature. It received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in September 2025, becoming the first FDA-cleared single-use, disposable robotic system for peripheral endovascular procedures.

Because LIBERTY is designed as a single-use device, it offers a differentiated business model compared with larger, capital-intensive surgical robots. Instead of requiring hospitals to make a major upfront equipment purchase, the system is positioned for per-procedure use, which the company believes can shorten the sales cycle and lower barriers to adoption.

Business Model and Revenue Sources

Microbot Medical's business model centers on developing, manufacturing, and distributing the LIBERTY system to hospitals, health systems, and interventional practices. Revenue is generated primarily through the sale of the disposable robotic systems used in individual procedures. The company has also pursued distribution partnerships, including agreements with third-party distributors in international markets and with government-services organizations to reach federal healthcare facilities.

The company historically incurred significant research and development expenses and, as an early-stage firm, has operated at a net loss for most of its history. Its financial profile is characteristic of a medical device company transitioning toward commercial scale, with revenue growth dependent on hospital adoption and utilization.

Markets and Competitive Positioning

Microbot Medical targets the peripheral endovascular market — catheter-based treatments for conditions affecting blood vessels outside the heart and brain — which the company estimates involves approximately 2.5 million procedures annually in the U.S. The company has broadened its stated ambitions toward adjacent areas such as interventional cardiology and neurovascular procedures. LIBERTY has been used across procedure types including prostatic artery embolization, uterine artery embolization, genicular artery embolization, and Y-90 radioembolization, reflecting its versatility.

Within medical robotics, Microbot competes with both established surgical-robot manufacturers and emerging interventional-robotics developers. Its differentiating market position rests on the LIBERTY system's single-use, remotely operated design, which targets radiation safety and ergonomic concerns for physicians.

Why Investors Follow MBOT

Investors follow MBOT largely because it represents a relatively early-stage opportunity in the high-growth medical robotics category. The shift toward minimally invasive procedures, combined with growing regulatory and professional attention to physician occupational radiation exposure and musculoskeletal injury, provides a long-term tailwind for robotic-assisted interventional tools. Microbot's single-use business model is also a point of interest, as it has the potential to generate recurring per-procedure revenue rather than relying on one-time capital sales.

The company's intellectual property portfolio — which has grown to dozens of issued and pending patents globally — and its collaborations with institutions such as Corewell Health and Emory University further support its innovation narrative and long-term growth prospects.

Risks and Important Considerations

As with any early-stage medical device company, Microbot Medical carries meaningful risks. The company is newly commercial and has a limited operating history generating revenue, and it has reported recurring operating losses. Its future depends heavily on successfully scaling adoption of a single flagship product, creating significant product concentration risk.

The company also operates in a highly regulated environment. Devices require FDA clearance or approval, and international expansion depends on additional regulatory milestones such as CE marking in Europe. Competition from larger, better-capitalized robotics and medical device firms is substantial, and there is no guarantee that hospital adoption will match the company's targets. Investors should also weigh typical risks associated with smaller companies, including potential share dilution from capital raises and sensitivity to broader healthcare spending and macroeconomic conditions.

AI Screener

For investors seeking to discover medical device stocks or other opportunities, Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps traders and investors identify ideas using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. The platform enables users to efficiently screen thousands of stocks and ETFs to surface ideas that match their own investment strategies.

Conclusion

Microbot Medical occupies a distinctive niche within the medical technology sector as the developer of the first FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. Its LIBERTY platform combines robotic precision with a disposable, per-procedure model that sets it apart from traditional capital-equipment surgical robots. While the company remains early in its commercial journey and faces the execution and regulatory risks typical of small medical device firms, its position in an expanding field of minimally invasive, radiation-conscious care keeps it a notable name for investors watching the evolution of endovascular medicine.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Profile

Industry
Biotechnology
Address
175 Derby Street
Phone
+1 781 875-3605
Employees
43
Web
https://www.microbotmedical.com

Details

Group
Domestic Stock Funds
Category
Health Services
Capitalization
74.55M
P/E Ratio
-4.44
Total Cash
67.37M
Projected Growth
N/A
Total Debt
876K
Revenue
346K
Risk (Beta)
0.31
Dividend Yield
N/A
Total Cash/Share
1.00
Total Debt/Equity
N/A
Revenue/Share
0.01 USD as % of share price
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company, which specializes in the research, design, development and commercialization of micro-robotics assisted medical technologies

Industry MedicalNursingServices

Industry
Biotechnology
Address
175 Derby Street
Phone
+1 781 875-3605
Employees
43
Web
https://www.microbotmedical.com
Who owns Microbot Medical? MBOT symbol Ownership - Tickeron.com